기호식품과 조리방법 선호도 비교

류화라,박영숙 대한피부미용학회 2005 대한피부미용학회지 Vol.3 No.1

Objective : We compared the difference of the facial skin type by food habit, frequency of food intake, food/cooking-method preference with a female college student of 131 person of the everyday activity to support and the appearance is healthy. Design : The skin type judged to a total facial skin surface sebum content. The statistical analysis were done by using SPSS11.0 for Win like average, SD, ANOVA, Pearson's Correlati- on of the facial skin type by food habit, frequency of food intake, food/cooking-method preference . Results : According to skin types, for the subjects who have oily skin, the following results were found: they regularly had three meals a day, enjoyed eat-out or snack at night. Their food behaviors were in higher level, and their food frequency, food/cooking-method pref- erence were in lower level. However, those who have dry skin frequently ate fried food and roasted fork, their frequency of excessive drinking was higher. Their food habits showed lower level, and their food frequency, food/ cooking-method preference showed higher level. Those who have normal skin had three times of meals a day, few eat-outs, little snack at night, little fried food and roasted fork, low frequency of excessive drinking, low frequency of drinking. Suggestion : It is suggested that the results above can be used as basic data to manage healthy faces and to control skin type. It is hoped that further studies should be done based on expanded subjects in age and number to identify skin types and their related factors according to age.

혈액제제로 인한 HIV 감염과 손해배상책임

류화신(Hwa Shin Ryoo)(柳和伸) 위기관리 이론과 실천 2011 Crisisonomy Vol.7 No.5

본 논문은 혈액을 원료로 하는 의약품, 즉 혈액제제로 인한 HIV(인간 면역결핍 바이러스, AIDS의 발병원인) 감염 문제에 대한 법적 쟁점을 다루고 있다. 한국혈우재단 등록 당시 HIV 검사에서 음성이던 B형 혈우병 환자들 중 12명이 1991년과 1993년 사이에 HIV 감염으로 진단되었으며, 2002년 9월 혈우병 환자들의 이러한 감염 원인이 국내 혈액응고제제 때문이라는 한 대학교수의 논문이 신문에 보도되면서 사회문제화 되었고, 그러한 환자측이 제약회사인 녹십자를 상대로 손해배상소송을 제기하였다. 본 사건은 2008년 1월 대법원에 상고되어 2011년 5월 현재 재판연구 중이다. 본 사건 자체도 장기미제사건이지만, 혈우병 환자의 HCV 감염으로 인한 타 소송에도 영향을 미쳐 당해 항소심 판단이 미뤄지고 있다. 이 사건의 핵심은 민법 제750조에 근거한 불법행위책임 성립요건으로서 제약회사의 과실 여부와 감염 원고들의 이 사건 혈액제제로 인한 AIDS 감염 여부, 구체적으로는 혈액관리에 있어서 고도의 주의의무의 내용과 인과관계 추정 여부에 따른 인과관계 증명 문제이다. 인과관계 부분에서 제1심 법원은 추정 이론을 도입하여 일부 감염 원고에 대한 손해배상청구권이 인정되면서 더 나아가 소멸시효 부분이 검토되었으나, 이 사건 항소심에서는 인과관계 성립이 부정되어 손해배상청구 자체가 성립되지 않았다. 본 논문에서는 약화사고 역시 전문적이고 기술적인 영역이므로 일반인의 원인 규명이 곤란하다는 문제점과 그에 따른 인과관계 증명완화 이론이 적용되어야 한다는 점이 강조되었다. 그리고 오염된 의약품으로 인하여 피해자에게 생명을 위협하는 치명적인 바이러스 감염 상태가 현존하는 한, 의약품을 개발하여 제조·공급하는 제약회사의 소멸시효 항변은 제한되어지거나, AIDS 질병의 특성상 HIV 감염으로 인한 손해배상채권의 소멸시효가 장기가 될 수 있도록 당해 소멸시효 규정을 해석할 것을 제안하였다. This study discusses main issues about AIDS infection of hemophiliacs caused by blood product. This contains summary of decision, and reasoning of the an appeal court(2005Na69245) and original court(2003Gahap1999) on that. According to article 750 of the Civil Law, the victim can demand damages if he prove cause and effect relationship besides the negligence of the wrongdoer. Under the traditional civil procedure law theory, most victims have much trouble with proving the causation in medicine accident, especially virus infection problem. And the appeal court turned down the lawsuit, saying the plaintiff's right to claim damages have already expired. I assert that those decisions cause the critical and embarrassing problem in the victim protection principle and legitimacy of the law. So, this study reviews the introduction of theory to relieve the burden of proof and a long-period sunset in substance for the benefit of victim.

영양소 부족섭취 또는 과잉섭취시의 피부유형분석

류화라,박영숙 순천향대학교 기초과학연구소 2006 순천향자연과학연구 논문집 Vol.12 No.2

..

줄기세포주 등록제도의 법적 분쟁을 둘러싼 법원 판단의 문제점 -대법원 2015. 6. 24. 선고 2013두24433 판결을 중심으로-

류화신 ( Ryoo Hwa-shin ),김민우 ( Kim Min-woo ) 홍익대학교 법학연구소 2016 홍익법학 Vol.17 No.4

2010년 5월, 황우석 박사는 2003년 4월에 수립한 `Sooam-hES1` 줄기세포주에 대하여 당시 생명윤리법에 근거하여 줄기세포주 등록을 신청하였다. 그러나 질병관리본부는 이 사건줄기세포주가 등록에 부적합하다는 이유로 신청을 반려하였다. 그러자 황우석 박사는 2010년 10월경 이 사건 처분에 대하여 이의신청을 하였고 질병관리본부가 이를 기각하자, 그해 11월경 질병관리본부를 상대로 줄기세포주 등록 반려처분 취소의 소를 제기하였다. 법원은 이 사건 줄기세포주 등록 신청 반려처분을 취소한다는 판결을 선고하였고, 이는 대법원에서 확정되었다. 그 후 2016년 11월, 질병관리본부는 그 등록을 허용하기로 이른다. 이러한 배경 하에서, 본 논문은 이미 수립된 배아줄기세포주의 등록과 관련한 윤리적ㆍ법적 문제를 대상으로 하여, 이 사건 처분을 둘러싼 법원의 입장 내지 판결 이유를 검토하고 법원의 판단에 아무런 문제점이 없는지를 살펴본다. 이를 위하여 줄기세포주 등록과 윤리와의 관계, 줄기세포주 등록제도의 도입 취지, 줄기세포주 등록의 법적 성격과 반려처분의 정당성 여부 등에 관하여 논의하고 있다. In May 2015, Professor Hwang Woo Suk applied for stem cell line registration for Sooam-hES1 stem cell line established in April 2003 based on the then Bioethics and Safety Act. However, the Korea Centers for Disease Control and Prevention reject the application, citing that the stem cell line of the case was inappropriate for registration. Then, Professor Hwang raised an appeal against the decision about October, 2010. As the KCDC dismissed it, he raised an action against the KCDC to cancel its rejection to the stem cell line registration in November of the year. The court ruled to cancel the rejection and the ruling was supported by the Supreme Court. In November, 2016, the KCDC permits its registration. In this background, this study focuses on the ethical and legal problems regarding the registration of already-established embryonic stem cell line and reviews the court`s stance about the CDC disposal and ground of ruling to see if there is any problem in court decision. To this end, this study discusses the relationship between stem cell line registration and ethics, purpose of introducing the stem cell line registration scheme, legal characteristics of stem cell line registration, legitimacy of the rejection, etc.

遠隔醫療에서 醫師의 責任原理

류화신(Hwa-Shin Ryoo) 한국비교사법학회 2005 比較私法 Vol.12 No.1

We are experiencing a fundamental change in delivery of health care today. A combination of information technology and medical care has given rise to a new type of medicine, i.e. telemedicine. Broadly defined, telemedicine is the transfer of electric medical data from one location to another. In order to facilitate the full-fledged development of telemedicine, it is particularly important that we dedicate ourselves to solving the legal problem. Korea is more or less retarded in amending the Medical Act to include the provisions of telemedicine and the Act came into force on March 30, 2002. According to article 30-2 of the Medical Act, telemedicine is to provide medical information or technique for the medical practitioner who is looking after a patient by means of the telecommunication such as computers and moving pictures. In connection with telemedicine, the problem is the medical malpractice. Paragraphs 3 and 4 of Article 30-2 are throughly examined and analysed. For example, Paragraphs 3 of Article 30-2 declares that a telemedical physician has an identical responsibility as the physician who consults a patient on a face-to-face basis. Paragraph 4 of the same Article says that if the fault is not evidently on the side of the consulting specialist, the physician who consults a patient on a face-to-face basis is responsible for the malpractice. This article discusses the liability regulation of telemedicine in medical law and provides brief assertions and theories in both facets of malpractice(breach-of-contract/torts) and transmission liability.

의료분쟁과 화해 -체계적인 의사소통과정을 통한 자율적 분쟁처리-

류화신 ( Hwa Shin Ryoo ) 한국의료윤리학회 2006 한국의료윤리학회지 Vol.9 No.2

This paper examines the relationship between poor physician-patient communication and litigation. The most important factor leading to a compromise in a medical dispute following an adverse event is a match between what the patient wants and what the physician provides. The following recommendations, based on the pew demonstration mediation and ADR project in Pensylvania hospitals, are given: 1) that physicians and other health care professionals develop an awareness of the communications skills most likely to be useful during disclosure conversations; 2) that hospitals recruit or train in-house experts available as consultants to aid in planning, conducting, and debriefing disclosure conversations; 3) that hospitals encourage physicians, patient safety officers, and risk managers to spend time planning before conducting disclosure conversations; 4) that physicians, hospital representatives, and other health care providers offer an appropriate apology after an adverse event or error; 5) that hospitals and senior physicians provide opportunities for debriefing and support for health care professionals after an error; 6) that hospitals use mediation as soon as practical after an adverse event to settle potential claims. Taking steps to improve disclosure conversations and using alternatives to litigating medical malpractice claims will help hospitals reduce costs, improve patient safety, and restore trust.

인간배아 유전자편집 관련 해외 규제 현황 및 국내 생명윤리법의 향후 과제

류화신,이민규 한국생명윤리학회 2017 생명윤리 Vol.18 No.2

Genome editing (also called gene editing) is a group of technologies that give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed, or altered at particular locations in the genome. Several approaches to genome editing have been developed. A recent one is known as CRISPR-Cas9, which is short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, more accurate, and more efficient than other existing genome editing methods. Genome editing is of great interest in the prevention and treatment of human diseases. Currently, most research on genome editing is done to understand diseases using cells and animal models. Scientists are still working to determine whether this approach is safe and effective for use in people. It is being explored in research on a wide variety of diseases, including single-gene disorders such as cystic fibrosis, hemophilia, and sickle cell disease. It also holds promise for the treatment and prevention of more complex diseases, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection. Ethical concerns arise when genome editing, using technologies such as CRISPR-Cas9, is used to alter human genomes. Changes made in the genes of an embryo could be passed to future generations. Embryo genome editing bring up a number of ethical challenges, including whether it would be permissible to use this technology to enhance normal human traits. This study examines the ethical and social issues related to human embryo genome editing, the contents of the related foreign legislations, and the reform of domestic law. 유전자편집은 유전체에서 특정 유전자의 염기서열을 인식하여 일부 DNA를 삽입, 제거, 수정하는 기술이며, 오늘날에는 CRISPR-Cas9이라는 유전자가위가 개발되면서 정확성과 신속성, 경제성이 크게 향상되었다. 유전자편집은 인간의 질병 예방과 치료에 큰 도움이 될 것으로 주목받고 있으나, 이러한 기술을 사용하여 인간배아의 유전자를 변형하는 것에 대해서는 세계적으로 상당한 윤리적 우려가 제기되고 있다. 따라서 본 논문은 이러한 윤리적 과제에 대하여 외국에서는 어떻게 인간배아 유전자편집을 규제하고 있는지에 관하여 검토하고 있다. 그리고 종국적으로는 이를 통하여 국내 생명윤리법 관련 규정의 개선방향을 도출하고 있다.

국립대학병원 설치 규율과 관련한 주요 논의에 대한 검토

류화신(Ryoo, Hwa-Shin) 충북대학교 법학연구소 2008 法學硏究 Vol.19 No.2

This paper examines some problems of regulations related on the establishment of national university hospital and the competent authorities of it. This study stars to discuss that legal definition of ths public health and medicine which is prescribed in "The law on the public health and medicine". This study also reviews the status of this public health and medical institution under the public health system. Then the study examines the similarity of purpose and contents of regulations related on the establishment of Seoul National University Hospital and regulations related on the establishment of national university hospital. So, I assert that regulations related on the establishment of Seoul National University Hospital are ought to be abolished and incorporated into regulations related on the establishment of national university hospital. And this paper reviews the competent authorities on national university hospital including Seoul National University Hospital will transfer to Ministry for Health, welfare and family affairs.

인간배아줄기세포 연구와 임상시험의 문제점

류화신 경북대학교 법학연구원 2013 법학논고 Vol.0 No.42

This paper examines the research and a clinical testing of human embryonic stem cells in Korea. Now the treatment of Human embryonic stem cells is in the spotlight in the regenerative medicine. However, a few problems still remain: an ethical problem of destroying human embryo and technological difficulty avoiding immune rejection of human embryonic stem cells, Though a clinical testing of human embryonic stem cells was first approved in 2011, it is not only the violation of regulations about external use of Human embryonic stem cells according to “a Law concerning Bioethics and Safety” but also has a problem in the extent of informed consent on clinical testing by an egg donor. For these discussions, this treatise reviews about the value of an human embryo as resources in the regenerative medicine and legal position of an embryo, looking into regulations on the research of an embryo and human embryonic stem cells. And I mention the problem of the absence in the regulation on the clinical testing of human embryonic stem cells and some considerations in enacting that regulation. 본 논문은 한국에서 배아줄기세포 임상연구의 문제점에 관하여 다루고 있다. 배아줄기세포치료는 재생의학 분야에서 획기적인 치료법으로 각광받고 있으나 인간 배아를 파괴한다는 윤리적 문제와 면역거부반응과 같은 안전성 문제를 안고 있다. 2011년에 배아줄기세포 임상시험이 국내에서 첫 승인되었지만 생명윤리및안전에관한법률상 배아줄기세포주의 체외이용에 관한 규정에 위배될 뿐 아니라 배아 생성시 난자제공자 등의 동의의 범위가 문제되고 있다. 이러한 논의를 위하여 이 논문은 먼저 배아의 자원으로서의 가치, 배아의 법적 지위에 관하여 살펴보고, 배아연구 및 배아줄기세포주의 연구에 관한 법규정을 검토한 다음, 배아줄기세포 임상시험에 관한 별도의 지침이 부재함에 따른 문제점과 그러한 지침을 마련함에 있어서 고려하여야 할 사항 등에 관하여 언급하고 있다.

생명공학에 관한 주요 법률의 개정방안 연구

류화신 ( Hwa Shin Ryoo ) 한남대학교 과학기술법연구소 2009 과학기술법연구 Vol.14 No.2

This Research examines some problems of the domestic laws related to the biotechnology and schemes for improvement of it. This Research examines and reviews the status of the laws related to the domestic biotechnology under the new government systems constituted by the amalgamation and centralization of governmental organization in 2008. In addition, the Research also examines the status of the laws related to the domestic biotechnology in accordance with the purposes of the laws, such as support and promotion of the biotechnology, improvement of the biotechnological infrastructure, effective management of biotechnological results, and proper regulations on the industries related to the biotechnology. After examining the legislative statuses of laws related to the biotechnology, this Research analyzes problems of the domestic laws related to the biotechnology and schemes for improvement of it, such as Biotechnology Support Act, LMO Act, and Life Ethics Act. Suggested schemes for the improvement of domestic laws related to the biotechnology are as below: (1) Enhancement of national biotechnology policy control function. The “Council for Comprehensive Biotechnology Policy” under the Minister of Science and Technology needs to be changed to the “Council for the Biotechnology Policy Adjustment” under the Prime Minister in order to control the conflicts of interest or the unclearness of the department`s service sectors. And participation of the civil experts to the policy making process must be guaranteed. (2) Improvement of systems and controls of laws related to the biotechnology. Laws related to Biotechnology are better to be specialized in the biotechnology support act and the biotechnology regulation act. Establishment of “the Special Committee for Biotechnology Legislative Deliberation” under the Ministry of Legislation as an organization for the adjustment of laws related to biotechnology could be considered. (3) Adjustment of laws related to bio-fusion technology(such as BT+NT, BT+IT). (4) Needs of the Ministry of Legislation`s affirmative adjustments for the related laws and regulation. In order to adjust some inconsistencies of the laws related to biotechnology, the Ministry of Legislation needs to aspire to choose the subject related to biotechnology when the Ministry selects the subjects for the adjustment of laws and regulations.